PYCXFPYC THERAPEUTICS LTD.

About PYC THERAPEUTICS LTD. (PYCXF)

PYC THERAPEUTICS LTD. (PYCXF) is a Biotechnology company headquartered in Nedlands, WA, Australia whose shares trade over-the-counter on the Pink tier.

PYC Therapeutics Limited, a drug-development company, engages in the discovery and development of novel RNA therapeutics for the treatment of genetic diseases in Australia. The company offers VP-001, a drug program which is Phase 1 clinical trial for the treatment of retinitis pigmentosa type 11; PYC-001, a drug candidate for the treatment of blinding eye disease; PYC-002 a drug program for the treatment of a severe neurodevelopmental disorder; and PYC-003, which is indicated to treat autosomal dominant polycystic kidney disease. PYC Therapeutics Limited has academic-industry collaborations with Murdoch University to support drug discovery and development efforts in the field of neurodegenerative disorders.

PYCXF key facts

Ticker symbol

PYCXF

Market tier

Pink

Sector

Healthcare

Industry

Biotechnology

Headquarters

Nedlands, WA, Australia

Estimated market cap

$2.63B (as of Apr 16, 2025)

Shares outstanding

3,935,910,623

Reporting standard

International Reporting: ASX - Australian Securities Exchange

Audit status

Audited

Fiscal year end

6/30

Explore more: Biotechnology stocks · Healthcare sector · Pink stocks · OTC stocks starting with P